It is clear that localized delivery of these drugs to the target organs will be critical for achieving maximal efficacy, such as activating TrkB in neurons with BDNF mimics or reducing tumor burden and preventing metastasis with TrkB antagonists. The gene discussed is NTRK2; the disease is neoplasm.